Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: Results of a randomized phase II trial

Meghan Karuturi; Anas Younes; Luis Fayad; Larry Kwak; Barbara Pro; Jatin Shah; Yasuhiro Oki; Rinata Simien; Mary Joy Liboon; Toni Hutto; Lei Feng; Sandra Horowitz; Yago Nieto; Paolo Anderlini; Amin Alousi; Uday Popat; L. Jeffrey Medeiros; Roberto Miranda; Michelle Fanale

doi:10.3109/10428194.2015.1032966

Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: Results of a randomized phase II trial

Meghan Karuturi, Anas Younes, Luis Fayad, Larry Kwak, Barbara Pro, Jatin Shah, Yasuhiro Oki, Rinata Simien, Mary Joy Liboon, Toni Hutto, Lei Feng, Sandra Horowitz, Yago Nieto, Paolo Anderlini, Amin Alousi, Uday Popat, L. Jeffrey Medeiros, Roberto Miranda, Michelle Fanale

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	445-447
Number of pages	3
Journal	Leukemia and Lymphoma
Volume	57
Issue number	2
DOIs	https://doi.org/10.3109/10428194.2015.1032966
State	Published - Feb 1 2016

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.3109/10428194.2015.1032966

Cite this

Karuturi, M., Younes, A., Fayad, L., Kwak, L., Pro, B., Shah, J., Oki, Y., Simien, R., Liboon, M. J., Hutto, T., Feng, L., Horowitz, S., Nieto, Y., Anderlini, P., Alousi, A., Popat, U., Medeiros, L. J., Miranda, R., & Fanale, M. (2016). Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: Results of a randomized phase II trial. Leukemia and Lymphoma, 57(2), 445-447. https://doi.org/10.3109/10428194.2015.1032966

Karuturi, M, Younes, A, Fayad, L, Kwak, L, Pro, B, Shah, J, Oki, Y, Simien, R, Liboon, MJ, Hutto, T, Feng, L, Horowitz, S, Nieto, Y, Anderlini, P, Alousi, A , Popat, U , Medeiros, LJ , Miranda, R & Fanale, M 2016, 'Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: Results of a randomized phase II trial', Leukemia and Lymphoma, vol. 57, no. 2, pp. 445-447. https://doi.org/10.3109/10428194.2015.1032966

@article{533786ca27e74ad8ac680bf3c1dab729,

title = "Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: Results of a randomized phase II trial",

author = "Meghan Karuturi and Anas Younes and Luis Fayad and Larry Kwak and Barbara Pro and Jatin Shah and Yasuhiro Oki and Rinata Simien and Liboon, {Mary Joy} and Toni Hutto and Lei Feng and Sandra Horowitz and Yago Nieto and Paolo Anderlini and Amin Alousi and Uday Popat and Medeiros, {L. Jeffrey} and Roberto Miranda and Michelle Fanale",

year = "2016",

month = feb,

day = "1",

doi = "10.3109/10428194.2015.1032966",

language = "English (US)",

volume = "57",

pages = "445--447",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "2",

}

TY - JOUR

T1 - Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma

T2 - Results of a randomized phase II trial

AU - Karuturi, Meghan

AU - Younes, Anas

AU - Fayad, Luis

AU - Kwak, Larry

AU - Pro, Barbara

AU - Shah, Jatin

AU - Oki, Yasuhiro

AU - Simien, Rinata

AU - Liboon, Mary Joy

AU - Hutto, Toni

AU - Feng, Lei

AU - Horowitz, Sandra

AU - Nieto, Yago

AU - Anderlini, Paolo

AU - Alousi, Amin

AU - Popat, Uday

AU - Medeiros, L. Jeffrey

AU - Miranda, Roberto

AU - Fanale, Michelle

PY - 2016/2/1

Y1 - 2016/2/1

UR - http://www.scopus.com/inward/record.url?scp=84955179441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955179441&partnerID=8YFLogxK

U2 - 10.3109/10428194.2015.1032966

DO - 10.3109/10428194.2015.1032966

M3 - Letter

C2 - 25804933

AN - SCOPUS:84955179441

SN - 1042-8194

VL - 57

SP - 445

EP - 447

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 2

ER -

Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: Results of a randomized phase II trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this